Eli Lilly has acquired drug candidates designed by Insilico Medicine for $2.75 billion, highlighting AI's growing role in pharmaceutical discovery. This significant investment underscores a broader trend, with the pharmaceutical industry committing $13.6 billion in a single week to AI-driven biotechnology. The deal signals a major shift in how new medicines are developed, leveraging artificial intelligence for accelerated research and development. AI
影响 Accelerates AI adoption in drug discovery, potentially leading to faster development of new medicines.
排序理由 Significant investment by a major pharmaceutical company in AI-driven drug discovery.
在 Mastodon — sigmoid.social 阅读 →
AI 生成摘要 · Google Gemini · 来自 5 个来源。 我们如何撰写摘要 →
